Intelligent Bio Solutions Inc. to Showcase Fingerprint Sweat PK Study at ADLM 2025 Clinical Lab Expo

Intelligent Bio Solutions Inc. (NASDAQ: INBS), a leader in non-invasive medical testing technologies, is set to present its groundbreaking pharmacokinetic (PK) study at the ADLM 2025 Clinical Lab Expo in Chicago. The study underscores the efficacy of the company's Intelligent Fingerprinting Drug Screening System, demonstrating that fingerprint sweat can accurately reflect codeine levels comparable to those found in blood and saliva. This advancement supports the system's potential as a non-invasive, rapid, and dignified solution for drug screening in various settings, including workplaces, clinical environments, and justice systems. Daniel Brown, Head of Clinical Affairs at INBS, will present the findings, which could significantly impact the future of drug testing methodologies. With a presence in over 450 accounts across 24 countries, INBS continues to lead the way in innovative testing solutions.